Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
News published by Savara Inc. concerning molgramostim (inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)), administered via an optimized eFlow® Technology nebulizer.